SE:CANTA Stock Latest News
Company AnnouncementsCantargia Appoints Nomination Committee Ahead of 2027 AGM3d ago
Company AnnouncementsCantargia to Spotlight IL1RAP-Targeted Pipeline at Key Healthcare Investor Conferences5d ago
Company AnnouncementsCantargia Bolsters Oncology Push With New Chief Medical Officer6d ago
Company AnnouncementsCantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer1M ago
Company AnnouncementsCantargia Ramps Up Investor Outreach with Series of September Conferences2M ago
Company AnnouncementsCantargia schedules Q2 2026 results release and investor conference call2M ago
Company AnnouncementsCantargia Expands Share Capital After Rights Issue Completion3M ago
Company AnnouncementsCantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer4M ago
Company AnnouncementsCantargia Raises SEK 75 Million in Undersubscribed Rights Issue and Grants Warrants to Fenja Capital4M ago
Company AnnouncementsCantargia Launches Phase 2 Prevention Trial of Nadunolimab in High‑Risk Lung Cancer Patients4M ago
Company AnnouncementsCantargia launches SEK 124m rights issue to fund antibody pipeline4M ago
Company AnnouncementsCantargia Raises Up to SEK 199 Million to Advance Nadunolimab Oncology Pipeline5M ago
Company AnnouncementsCantargia Raises Funds to Expand Nadunolimab Strategy in Cancer and Blood Disorders5M ago
Company AnnouncementsCantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate5M ago



